Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, NY 10065, USA.
Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, NY 10065, USA.
Free Radic Biol Med. 2013 Sep;62:37-46. doi: 10.1016/j.freeradbiomed.2013.04.016. Epub 2013 Apr 19.
The constant high energy demand of neurons makes them rely heavily on their mitochondria. Dysfunction of mitochondrial energy metabolism leads to reduced ATP production, impaired calcium buffering, and generation of reactive oxygen species. There is strong evidence that mitochondrial dysfunction results in neurodegeneration and may contribute to the pathogenesis of Huntington's disease (HD). Studies over the past few years have implicated an impaired function of peroxisome proliferator-activated receptor (PPAR)-γ coactivator-1α (PGC-1α), a transcriptional master coregulator of mitochondrial biogenesis, metabolism, and antioxidant defenses, in causing mitochondrial dysfunction in HD. Here we have attempted to discuss in a nutshell, the key findings on the role of PGC-1α in mitochondrial dysfunction in HD and its potential as a therapeutic target to cure HD.
神经元对能量的高需求使它们严重依赖于线粒体。线粒体能量代谢功能障碍会导致 ATP 生成减少、钙缓冲能力受损以及活性氧的产生。有强有力的证据表明线粒体功能障碍会导致神经退行性变,并可能导致亨廷顿病 (HD) 的发病机制。过去几年的研究表明,过氧化物酶体增殖物激活受体 (PPAR)-γ 共激活因子-1α (PGC-1α) 的功能受损,作为线粒体生物发生、代谢和抗氧化防御的转录主调控因子,与 HD 中的线粒体功能障碍有关。在这里,我们试图简要讨论 PGC-1α 在 HD 中线粒体功能障碍中的作用及其作为治疗 HD 的潜在治疗靶点的关键发现。